Literature DB >> 6464168

Cyclosporine does not prevent cytoplasmic calcium changes associated with lymphocyte activation.

S Metcalfe.   

Abstract

The recent development of fluorescent reagents that are sensitive to calcium ions has made it possible to quantitate cytoplasmic calcium levels of lymphocytes. The cytoplasmic calcium concentration more than doubles within the first few minutes following lymphocyte stimulation. Here I show that it is likely that this increase in calcium is an absolute requirement for mitogenic commitment. Brief exposure of T cells to concanavalin A (Con A) is sufficient to stimulate cell division, provided that extracellular calcium ions are available to the cells at the time of exposure to mitogen--no mitogenesis occurs if extracellular calcium is below 10(-5)M. Commitment to mitosis requires both Con A acting at the cell surface and a source of extracellular calcium, so it follows that the plasma membrane is implicated in the control of cytoplasmic calcium changes. The lipid-soluble nature of cyclosporine (Cys) results in the partitioning of this drug into the plasma membrane of lymphocytes; the possibility arises that Cys might inhibit lymphocyte activation by perturbing membrane structure so as to alter regulatory fluxes in cytoplasmic calcium. Experiments reported here show that early changes in cytoplasmic calcium levels of activated T cells occur normally in the presence of Cys.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6464168     DOI: 10.1097/00007890-198408000-00014

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  12 in total

1.  Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium.

Authors:  M L Jordan; S Hignet; J Wright; R A Hoffman; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

2.  Activation and proliferation signals in mouse B cells. VII. Calcium ionophores are non-mitogenic polyclonal B-cell activators.

Authors:  G G Klaus; M K Bijsterbosch; M Holman
Journal:  Immunology       Date:  1985-10       Impact factor: 7.397

3.  Inhibition by cyclosporin A of a Ca2+-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress.

Authors:  M Crompton; H Ellinger; A Costi
Journal:  Biochem J       Date:  1988-10-01       Impact factor: 3.857

Review 4.  The influence of cyclosporin A on cell-mediated immunity.

Authors:  A W Thomson; L M Webster
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

5.  Cyclosporine does not inhibit mitogen-induced inositol phospholipid degradation in mouse lymphocytes.

Authors:  M K Bijsterbosch; G G Klaus
Journal:  Immunology       Date:  1985-11       Impact factor: 7.397

6.  Serum markers of immune activation and liver allograft rejection.

Authors:  E Lalli; R Meliconi; R Conte; A Mancini; M Uguccioni; G F Stefanini; G Gasbarrini
Journal:  Dig Dis Sci       Date:  1992-07       Impact factor: 3.199

7.  Activation and proliferation signals in mouse B cells. IX. Protein kinase C activators synergize with non-mitogenic anti-immunoglobulin antibodies to drive B cells into G1.

Authors:  M K Bijsterbosch; J B McLaughlin; M Holman; G G Klaus
Journal:  Immunology       Date:  1988-05       Impact factor: 7.397

8.  Inhibition of programmed cell death by cyclosporin A; preferential blocking of cell death induced by signals via TCR/CD3 complex and its mode of action.

Authors:  D Yasutomi; C Odaka; S Saito; H Niizeki; H Kizaki; T Tadakuma
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

9.  Partial inhibition of human neutrophil activation by FK-506 at supratherapeutic concentrations.

Authors:  K Wenzel-Seifert; R Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

Review 10.  Regulation of lymphocyte growth by antagonists of interleukin-2 or its cellular receptor.

Authors:  G N Gaulton; J F Markmann
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.